Latest Financials News

Yowie Group has arranged a $1 million short-term funding facility from parent Keybridge Capital to manage cash flow while investigating former directors' use of funds and intra-group loans.

Australian Pacific Coal faces creditor pressure as Vitol Asia reserves rights on a parent guarantee, while the company insists it remains solvent amid uncertainty.

Ironbark Capital Limited has announced an on-market buy-back of up to 10.46 million ordinary shares, commencing July 21, 2025, and running through to July 2026. This move signals a strategic capital management initiative without requiring shareholder approval.

Pentanet Limited has secured a $2 million finance facility to fund the final payment for its 5G spectrum licence, reinforcing its growth strategy in telecommunications and cloud gaming.

Rimfire Pacific Mining accepts an arbitration ruling that reinstates key project agreements and prepares for a capital raising amid continued voluntary suspension.

Magnetic Resources NL has reported a significant 22% increase in gold resources at its Lady Julie Gold Project, now containing over 2.14 million ounces, while securing a key Native Title Agreement that clears the path for mining leases and development.

Connexion Mobility reported steady revenue growth and a 7% increase in net profit before tax for Q4 FY25, driven by expanding SaaS subscriptions and strategic product enhancements.

Orbminco Limited has executed a binding agreement to acquire the Majestic North Gold Project in Western Australia and commenced maiden drilling, marking a significant step in its growth strategy.

Connected Minerals reports promising uranium grades from its maiden drilling at Namibia’s Etango North-East project, aligning closely with nearby world-class deposits, while advancing rare earth exploration in Western Australia.

Mineral Commodities Ltd updates investors on the postponed completion of its Skaland Graphite Project sale due to the buyer's funding constraints, with new non-refundable payments and operational support commitments outlined.

TAL Dai-ichi Life Australia has obtained all necessary regulatory approvals, including from APRA, to finalize its minority investment in Challenger Limited, acquiring a 19.9% equity stake.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.